Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3.

Journal of viral hepatitis - 1 Jan 2008

Powis J, Peltekian K M, Lee S S, Sherman M, Bain V G, Cooper C, Krajden M, Deschenes M, Balshaw R F, Heathcote E Jenny, Yoshida E M

Abstract excerpt

Chronic hepatitis C virus (HCV) infections with genotype 2 or 3 are associated with favourable sustained virologic response (SVR) rates. However, genotype 3 may respond less well. We reassessed all treatment-naive patients with genotype 2 and 3 participating in a large expanded-access, non-randomized, open-label trial, evaluating 180microg pegylated interferon (peg-IFN) alpha-2a (40kD) once weekly and 800 mg/day...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Canada
Share to Drug Administration Schedule

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Multivariate Analysis

Share to Polyethylene Glycols

Share to Ribavirin

Source

Open in PubMed Open full text

Identifiers

PMID: 18088245
DOI: 10.1111/j.1365-2893.2007.00889.x
PMCID: PMC2229559

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3.PMID 18088245Read ↗

Hepatitis C Virus: Current and Evolving Treatments for Genotypes 2 and 3.Semantic proximity Read ↗

Review article: HCV genotype 3 – the new treatment challenge.Semantic proximity Read ↗

Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.Semantic proximity Read ↗

Hepatitis C virus infection: Are there still specific problems with genotype 3?Semantic proximity Read ↗

Closing the Gap: The Challenges of Treating Hepatitis C Virus Genotype 3 Infection.Semantic proximity Read ↗

Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3.Semantic proximity Read ↗

Hepatitis C Genotype 3 Infection: Pathogenesis and Treatment Horizons.Semantic proximity Read ↗

A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3.Semantic proximity Read ↗

Therapy for hepatitis C genotype 3: moving forward.Semantic proximity Read ↗

Predictive factors for sustained virological response after treatment with pegylated interferon α-2a and ribavirin in patients infected with HCV genotypes 2 and 3.Semantic proximity Read ↗

Hepatitis C virus genotype 3: a genotype that is not 'easy-to-treat'.Semantic proximity Read ↗

Do differences exist between chronic hepatitis C genotypes 2 and 3?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.